SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunex
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: The Thrifty Investor who wrote (92)9/14/1997 2:11:00 PM
From: shdu   of 656
 
More comments:

>>I think that $7,000 per year is too high. Yes, some people would pay >>this amount, and I'm not saying that the drug would not be worth >>this price to many. However, setting the price this high would invite a backlash from Congress andinsurers. I don't believe that >>Roche would want to risk the negative publicity.

Yes, Roche did risk the negative publicity with its HIV protease inhibitor drug INVIRASE. The initial price for INVIRASE was $7,2000 per year, and this price set the introduction prices for later versions of protease inhibitors from other companies. $7000 per year is probably a reasonable introduction price for an effective drug for a disease as bad as RA. I would be suprised if the price is much lower.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News